Key Questions on PARP Inhibitors in Ovarian Cancer: Experts Evaluate the Latest Evidence

In this interactive recording of a live CCO webinar experts discuss the latest data on safely and effectively leveraging PARP inhibitors for treating patients with ovarian cancer. Download the slides for use in your own presentations!

Share

Program Content

No activities added yet

Activities

<i>EP</i>: PARPi Questions in OC
ExpressPoints
Key Questions on PARP Inhibitors in Ovarian Cancer: Experts Evaluate the Latest Evidence
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 06, 2021

Expires: July 05, 2022

PARPi in Ovarian Cancer
Global Experience Using PARP Inhibitors in the Treatment of Ovarian Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 01, 2021

Expires: June 30, 2022

Managing PARPi related AEs
How Can We Proactively Manage PARP Inhibitor–Related Adverse Events to Improve Quality of Life?
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 01, 2021

Expires: June 30, 2022

PARPi combinations in OC
Should PARP Inhibitors be Used Alone or in Combinations for Ovarian Cancer? The Influence of Patient and Disease Factors
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 01, 2021

Expires: June 30, 2022

PARPi in practice
How Do You Approach the Use of PARP Inhibitors in Practice?
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 01, 2021

Expires: June 30, 2022

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca